|
 |
| |
|
|
| |
| |
11/20/2008
NHS Sight Tests Top 11 Million After 14 Per Cent Rise Since 2002-03, Report Shows, England
Just over 11 million NHS sight tests took place in England in 2007-08, nearly 1.4 million more than in 2002-03, new figures from The NHS Information Centre show. The report, General Ophthalmic Services, Activity Statistics for England and Wales, Year Ending 31 March 2008, also shows there were nearly 330,000 of these sight tests at a patients' home or residential home in 2007-08, 75,000 (29.3 per cent) more than in 2002-03.
more info
|
11/19/2008
First Retinal Prosthesis Study Of Its Kind Seeks To Partially Restore Vision To The Blind
Second Sight® Medical Products, Inc., the leading developer of retinal prostheses for the blind, announced that it will increase patient enrollment for the ArgusTM II Retinal Implant study throughout clinical trials sites within Europe. The three-year feasibility study is currently underway in the United States, Europe and Mexico for people with Retinitis Pigmentosa (RP), a genetic eye disease that causes blindness.
more info
|
11/19/2008
Will Glaucoma Be The First Neurodegenerative Disease To Be Cured?
"More than in any preceding year," says Glaucoma Research Foundation (GRF) President and CEO Thomas M. Brunner, "there is a heightened sense of anticipation around the annual Research Overview by the four principal investigators of the GRF-funded Catalyst For a Cure (CFC) research consortium that opens GRF's 31st Anniversary Benefit and Celebration at 5 pm, Wednesday, January 28, 2009, in San Francisco's legendary Palace Hotel.
more info
|
11/19/2008
Delcath Systems Granted Orphan-Drug Designations For Cutaneous And Ocular Melanoma
Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary liver cancer treatment for melanoma metastatic to the liver, announced that the United States Food and Drug Administration ("FDA") granted to Delcath two orphan-drug applications for the drug melphalan. Delcath was granted designations of the drug melphalan for the treatment of patients with cutaneous as well as ocular melanoma.
more info
|
11/18/2008
Experimental Drug RGN-259 Promotes Healing In Patients With Non-Healing Corneal Ulcers - Four Patients Treated Under "Compassionate Use" IND
REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) announced today that its ophthalmic drug candidate, RGN-259, was used to treat four neurotrophic keratitis patients with non-healing eye ulcers caused primarily by the herpes zoster virus under a "Compassionate Use" IND (Investigational New Drug application). RGN-259 is a sterile eye drop formulation of Tβ4 being developed by RegeneRx for use in treating ophthalmic wounds and related disorders. Dr.
more info
|
|
|
| |
|
|
|
|
| |
|
|
|
|
|
